Our portfolio companies over the years

Actar was a fully owned subsidiary of KDventures, enabling academic ideas by pre-clinical research services focused on innovative drug targets.

Akinion Pharmaceuticals developed kinase receptor inhibitors for treatment of acute myeloid leukemia. The company's phase 1/2 clinical study with AKN-028 was halted due to liver toxicity in a small number of patients. In 2016, KDventures divested its...

AnaCardio is developing a new form of drug concept that protects cardiac tissue in conjunction with heart failure. AnaCardio’s clinical candidate drug is being developed to restore the heart’s normal muscular function and blood circulation with ground-breaking...

Antrad Medical offers thawing devices and thawing of sensitive biological material. This is made possible through their radio frequency (RF) technology.

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focusing on developing and commericliazing novel cancer therapeutics targeting DNA damage response (DDR) pathways.

Accuro Immunology was a biomedical R&D company focusing on the development of novel immunotherapies for treatment of cancer. The company developed a new concept, TEIPP-based immunotherapy in collaboration with scientists at Karolinska Institutet, Sweden,...

Accuro Immunology was a biomedical R&D company focusing on the development of novel immunotherapies for treatment of cancer. The company developed a new concept, TEIPP-based immunotherapy in collaboration with scientists at Karolinska Institutet, Sweden,...

Absorber developed products to facilitate more successful transplantations. The company launched its standardized transplantation test XM-ONE® in 2006, used to evaluate organ transplantation risk. The company was aquired by Allenex AB in 2010 which was...

BioCis Pharma developed topical therapies for dermatology and locally administered products in oncology. The company merged with Lx Therarapies to Laurantis Pharma in 2011 and was later aquired by Herantis Pharma.

Avaris developed primarily cancer therapies based on prorietary knowledge in cell and gene therapy.

Axelar developed a unique first-in-class treatment for different types of cancers. The lead candidate, Insulin-like growth factor-1 receptor (IGF-IR) inhibitor AXL1717, has shown pronounced antitumor activity in clinical setting. In 2017, the FDA and...

BioArctic is a Swedish research-based biopharma company focusing on disease-modifying treatments for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and ALS. The FDA approved LEQEMBI™ (lecanemab-irmb) under the Accelerated...

BioChromix developed in vitro diagnostic tests for neurodegenerative diseases that involve misfolded proteins, such as Alzheimer’s. The company was acquired by Cadila Pharmaceuticals Sweden in 2014.

Bioneris developed the alpha trinositol molecule for oncology. Alpha trinositol and its derivatives play an essential rolw in the development of many cancer types.

BioResonator developed and sold advanced intraocular pressure gauges used to diagnose glaucoma. The technology used in the instrument was developed by researchers at Umeå University.

Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway and several other places worldwide. The company’s lead candidate BSG005,...

BOOST Pharma was founded based on research from Karolinska Institutet, focusing on novel cell therapy treatments for osteogenesis imperfecta, OI. The company’s treatment has a unique position on the market, since it targets the underlying condition causing...

C-RAD is a medtech company originating from Karolinska Institutet and KTH that develops surface-guided imaging solutions for radiation therapy.

Calabar International originated from Karolinska Institutet and developed drugs for the treatment of xerostomia, or dry mouth. The company was divested in 2011.

CarbGraft developed ChitografTM, a proprietary bone graft technology based on chitosan for applications in oral implants, orthopedics and other medical fields.

Clanotech is developed compounds for the treatment of solid cancers and age-related macular degeneration (AMD). Clanotech’s lead candidate drug was an inhibitor of the alpha5beta1-integrin receptor. KDventures sold its shares to Rosetta Capital via an...

Cogmed, founded in 2001, digitial programs for memory training programs for people with concentration difficulties. The company was sold to Pearson Overseas Holding Limited in 2010.

CytoGuide was a danish biotech company that focused on drug development for the treatment of monocyte- and macrophage-related diseases.

DermaGen developed topical therapeutics based on novel and proprietary antimicrobial peptides (AMPs). Karolinska Development owned its holding in the company through Pergamum AB (later Promore Pharma). KDventures divested its entire holding in the company...

Dilafor AB is a women’s health company based in Stockholm, Sweden, developing tafoxiparin for obstetric indications, with particular reference to protracted labor and associated complications. Protracted labor represents a significant unmet clinical need...

Eribis Pharmaceuticalsdeveloped new drugs for the treatment of cardiovascular diseases, specifically myocardial infarction.

EvoStem based in Tampere, Finland, developed treatment methods based on stem cell technology and tissue engineering for regenerative medicine. The company's product TendoStem was on the market in Scandinavia for tendon and ligament injuries in horses....

Forendo Pharma was founded in 2013 in Turku, Finland, and built a scientific platform around HSD17B1. Its most advanced drug candidate, OG-6219, was developed for endometriosis. Organon acquired Forendo in December 2021 in a deal worth up to USD 945 million....

Genordia produced biotechnical reagents in the siRNA area for use in gene silencing experiments. They used a unique proprietary technology, which enabled that very rapid, reliable and cost effective tools could be offered to molecular biologists.

GilGene was an oncology company focused on Hedgehog-signaling for targeted cancer treatment.

Global Genomics was a Swedish company with a patented technology for rapid and accurate global expression analysis of genes. The company merged with Genizon BioSciences.

HBV Theranostica developed a marker for the assessment of which Hepatitis B patients are responders to a treatment with interferon-alpha.

Henlez is a Danish company with a pre-clinical development program for an enzyme-based, topical application directed towards the chronic dermatological condition hidradenitis suppurativa.

IMED developed human antibodies for the treatment of immune disorders and diseases associated with deregulation of cell death; apoptosis.

IPAB developed a treatment method for patients addicted to nicotine based on new vaccine technology and innovative pharmacological approaches.

InDex Pharmaceuticals develops drugs for the treatment of immunological diseases. Their lead drug candidate cobitolimod, is currently in phase 3 clinical development to treat ulcerative colitis. KDventures sold its holding in 2011. InDex shares have been...

Inhalation Sciences has developed a research and development platform which provides the possbility for companies developing inhaled pharmaceuticals to generate high quality data during the early development stage. KDventures sold its holding in the company...

Inhalox developed technology for oxygen treatment. The company developed a process that produces pure oxygen from air, using a new class of oxygen selective agents for air separation.

Jederstrom Pharmaceuticals developed new formulations for oral delivery of therapeutic proteins, such as insulin. The patented technology enabled the formation of a complex between biomolecules and myaluronan that was many times smaller than the original...

Lipidor is a research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The company develops topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial...

Lipopeptide, which was owned by Pergamum AB (later Promore Pharma) from 2010, was a biopharmaceutical company specialized in the development of therapeutic peptides for treatment of hard-to-heal wounds. KDventures divested its entire holding in the company...

Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need. The Company’s near-term focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition.

NeoDynamics has developed an innovative biopsy system called NeoNavia®. This biopsy system builds on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. The company is listed on the Swedish stock market via Spotlight...

NephroGenex Inc developed Pyridorin™ (pyridoxamine dihydrochloride) as a treatment to slow the progression of diabetic kidney disease. Pyridorin was acquired for shares from BioStratum, Inc in 2014. NephroGenex listed on Nasdaq in 2014. The company was...

NeuroTherapuetics developed cell processing technology to regulate neruogenesis and stem cell differentiation for the treatment of Parkinson's disease.

NovaSAID developed new drugs for the treatment of inflammatory diseases such as rheumatoid arthritis and osteoarthritis.

OmnioHealer was developing products based on plasminogen for wound healing applications with a focus on ear diseases. KDventures owned its holding in the company through Pergamum AB (later Promore Pharma). KDventures divested its entire holding in the...

Oncopeptides is a biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. Oncopeptides uses its proprietary PDC platform to develop peptide-linked drugs that rapidly and selectively deliver chemotherapy...

OncoReg developed drugs based on inhibition of the enzyme tripeptidylpeptidase which increases the senstitivity of cancer tumors to radiation and chemotherapy.

OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they...

Pergamum AB gathered KDventures' dermatology and wound healing portfolio. The company changed its name to Promore Pharma in 2016. Promore Pharma is a biopharmaceutical company that develops peptide-based drug candidates in scarring and wound treatment....

Pharmanest, now Palette Life Science, offers products in radiotherapy and interventional oncology procedures, urology and colorectal conditions. KDventures divested its shares in 2019.

PharmaSurgics developed a treatment for prevention of harmful scarring and promotion of wound healing after surgery. The product concept was based on proprietary synthetic peptides of human lactoferrin which have strong anti-inflammatory and anti-infectious...

PharmNovo develops innovative drugs for the treatment of nerve pain (neuropathic pain). Neuropathic pain is one of the most prevalent types of chronic pain and affects up to 10 per cent of the population. PharmNovo’s novel drug candidate, based on a drug...

Promimic is a growth company that manufactures, markets, and sells biomaterials for improved osseointegration (bone healing) to leading companies in the markets for orthopedic and dental implants. The company has its origins in research at Chalmers University...

ProNoxis develops new low molecular weight drugs for the treatment of chronic inflammation such as rheumatoid arthritis, multiple sclerosis and peritonitis. KDventures divested its shares in 2012.

Sidec Technologies offered the pharmaceutical industry visualization of the 3-dimensional shape of proteins and how they interact in situ, ie in their biological environment, through electron microscopy. KDventures sold its shares in Sidec to KIHAB in...

SoftCure Pharmaceuticals modified existing potent drugs with high toxicity to topically administred drugs, enabling local treatment without systemic side effects.

SpectraCure is developing systems for the treatment of internal solid cancer tumours. The method is based on photodynamic therapy (PDT) where a light-activated drug is activated through laser to treat the tumor. SpectraCure’s share is listed on the Nasdaq...

SVF Vaccines develops vaccines and immunotherapies to prevent and treat life-threatening diseases based on technology developed at the Karolinska Institute in Stockholm. Current development is focused on a therapeutic vaccine for chronic hepatitis B and...

Umecrine Cognition is developing a completely new type of drug for neurological disorders in the brain that can occur as a result of a number of underlying diseases and lead to severely reduced cognition and alertness. The results from an internationally...

Triple Crown developed and commercialized its sterol-based cholesterol-lowering ingredient Prolocol to be incorporated into functional food products and nutraceuticals.

XSpray Pharma is a pharmaceutical company with several product candidates in clinical development, the first XS004 dasatinib recently filed with the FDA. The company uses its innovative, patented RightSize™ technology to develop improved versions of marketed...